{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:15:23Z","timestamp":1775063723153,"version":"3.50.1"},"reference-count":27,"publisher":"Japanese Society of Internal Medicine","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,8,1]]},"DOI":"10.2169\/internalmedicine.4856-24","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T17:13:45Z","timestamp":1738343625000},"page":"2301-2306","source":"Crossref","is-referenced-by-count":1,"title":["Use of Ursodeoxycholic Acid and the Risk of Severe Coronavirus Disease 2019 in Elderly Patients with Viral Hepatitis"],"prefix":"10.2169","volume":"64","author":[{"given":"Kazuya","family":"Okushin","sequence":"first","affiliation":[{"name":"Department of Infection Control and Prevention, Graduate School of Medicine, The University of Tokyo, Japan"},{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Ikeuchi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Saito","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Kishida","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Kado","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Fujishiro","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoji","family":"Moriya","sequence":"additional","affiliation":[{"name":"Division of Infection Control and Prevention, Education Research Center, Tokyo Healthcare University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yotsuyanagi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Koike","sequence":"additional","affiliation":[{"name":"Kanto Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeya","family":"Tsutsumi","sequence":"additional","affiliation":[{"name":"Department of Infection Control and Prevention, Graduate School of Medicine, The University of Tokyo, Japan"},{"name":"Department of Infectious Diseases, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet 399: 1513-1536, 2022.","DOI":"10.1016\/S0140-6736(21)02796-3"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Li Z, Hu P, Qu L, et al. Molecular epidemiology and population immunity of SARS-CoV-2 in Guangdong (2022-2023) following a pivotal shift in the pandemic. Nat Commun 15: 7033, 2024.","DOI":"10.1038\/s41467-024-51141-y"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Al-Aly Z, Davis H, McCorkell L, et al. Long COVID science, research and policy. Nat Med 30: 2148-2164, 2024.","DOI":"10.1038\/s41591-024-03173-6"},{"key":"4","unstructured":"4. Schilling WHK, Mukaka M, Callery JJ, et al. Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): a double-blind, randomised, placebo-controlled trial. PLoS Med 21: e1004428, 2024."},{"key":"5","unstructured":"5. Brevini T, Maes M, Webb GJ, et al. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature 2022."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. John BV, Bastaich D, Webb G, et al. Ursodeoxycholic acid is associated with a reduction in SARS-CoV-2 infection and reduced severity of COVID-19 in patients with cirrhosis. J Intern Med 293: 636-647, 2023.","DOI":"10.1111\/joim.13630"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Lee H, Kim MG, Yeom SW, et al. Association between ursodeoxycholic acid and clinical outcomes in patients with COVID-19 infection: population-based cohort study. JMIR Public Health Surveill 10: e59274, 2024.","DOI":"10.2196\/59274"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Colapietro F, Angelotti G, Masetti C, et al. Ursodeoxycholic acid does not improve COVID-19 outcome in hospitalized patients. Viruses 15: 1738, 2023.","DOI":"10.3390\/v15081738"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Marrone G, Covino M, Merra G, et al. Ursodeoxycholic acid does not affect the clinical outcome of SARS-CoV-2 infection: a retrospective study of propensity score-matched cohorts. Liver Int 44: 83-92, 2024.","DOI":"10.1111\/liv.15736"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Corpechot C, Verdoux M, Frank-Soltysiak M, Duclos-Vall\u00e9e JC, Grimaldi L. Exploring the impact of ursodeoxycholic acid therapy on COVID-19 in a real-word setting. J Med Virol 96: e29418, 2024.","DOI":"10.1002\/jmv.29418"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Okushin K, Kurano M, Yatomi Y, et al.; UTH-UDCA Study Group. Ursodeoxycholic acid for coronavirus disease 2019 prevention. J Intern Med 295: 106-109, 2024.","DOI":"10.1111\/joim.13704"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Delgado JF, Vidal M, Juli\u00e0 G, et al. Validation of N protein antibodies to diagnose previous SARS-CoV-2 infection in a large cohort of healthcare workers: use of Roche Elecsys<sup>\u00ae<\/sup> immunoassay in the S protein vaccination era. Viruses 15: 2023.","DOI":"10.3390\/v15040930"},{"key":"13","unstructured":"13. Medical Data Vision Co. Ltd. MDV EBM insight [Internet]."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Yamana H, Moriwaki M, Horiguchi H, Kodan M, Fushimi K, Yasunaga H. Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. J Epidemiol 27: 476-482, 2017.","DOI":"10.1016\/j.je.2016.09.009"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Yasunaga H. Real world data in Japan: chapter ii the diagnosis procedure combination database. Ann Clin Epidemiol 1: 76-79, 2019.","DOI":"10.37737\/ace.1.3_76"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Guo L, Shi Z, Zhang Y, et al. Comorbid diabetes and the risk of disease severity or death among 8807 COVID-19 patients in China: a meta-analysis. Diabetes Res Clin Pract 166: 108346, 2020.","DOI":"10.1016\/j.diabres.2020.108346"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Huang S, Wang J, Liu F, et al. COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study. Hypertens Res 43: 824-831, 2020.","DOI":"10.1038\/s41440-020-0485-2"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Liu Y, Pan Y, Yin Y, Chen W, Li X. Association of dyslipidemia with the severity and mortality of coronavirus disease 2019 (COVID-19): a meta-analysis. Virol J 18: 157, 2021.","DOI":"10.1186\/s12985-021-01604-1"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Attaway AA, Zein J, Hatipo\u011flu US. SARS-CoV-2 infection in the COPD population is associated with increased healthcare utilization: an analysis of Cleveland clinic&apos;s COVID-19 registry. EClinicalMedicine 26: 100515, 2020.","DOI":"10.1016\/j.eclinm.2020.100515"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kutsuna S, Onozuka D, Asano K, Matsunami K, Matsuoka T. Cross-sectional surveillance study of long COVID in Toyonaka city, Osaka prefecture, Japan. J Infect Chemother 30: 511-515, 2024.","DOI":"10.1016\/j.jiac.2023.12.006"},{"key":"21","unstructured":"21. Ministry of Health, Labour and Welfare. Visualizing the data: information on COVID-19 infections. [cited 2024 Sep 16]. Available from: https:\/\/covid19.mhlw.go.jp\/en\/"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis 21: 855, 2021.","DOI":"10.1186\/s12879-021-06536-3"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Domovitz T, Ayoub S, Werbner M, et al. HCV infection increases the expression of ACE2 receptor, leading to enhanced entry of both HCV and SARS-CoV-2 into hepatocytes and a coinfection state. Microbiol Spectr 10: e0115022, 2022.","DOI":"10.1128\/spectrum.01150-22"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Singh MK, Mobeen A, Chandra A, Joshi S, Ramachandran S. A meta-analysis of comorbidities in COVID-19: which diseases increase the susceptibility of SARS-CoV-2 infection? Comput Biol Med 130: 104219, 2021.","DOI":"10.1016\/j.compbiomed.2021.104219"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Shaikh OS, Yan P, Rogal S, Butt AA. The impact of COVID-19 on the clinical course and outcome of patients with cirrhosis: an observational study. Health Sci Rep 7: e2207, 2024.","DOI":"10.1002\/hsr2.2207"},{"key":"26","unstructured":"26. Ge J, Far AT, Digitale JC, Pletcher MJ, Lai JC; National COVID Cohort Collaborative (N3C) Consorlium. Decreasing case fatality rates for patients with cirrhosis infected with SARS-CoV-2: a national COVID cohort collaborative study. Clin Gastroenterol Hepatol. Forthcoming."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Laurent T, Simeone J, Kuwatsuru R, et al. Context and considerations for use of two Japanese real-world databases in Japan: Medical Data Vision and Japanese Medical Data Center. Drugs Real World Outcomes 9: 175-187, 2022.","DOI":"10.1007\/s40801-022-00296-5"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/15\/64_4856-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:17:04Z","timestamp":1754108224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/15\/64_4856-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":27,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4856-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"article-number":"4856-24"}}